Precision Medicine

Nanomedicine Market to Nearly Triple to $581.2B by 2034

Pune, India – September 24, 2026 -- The global nanomedicine market reached USD 207.91 billion in 2025 and is projected to hit USD 581.2 billion by 2034, expanding at a 12.1% compound annual growth rate, according to a new report from Maximize Market Research.

North America commands the largest share on pharmaceutical R&D strength

North America held the largest share of the market in 2025, driven by advanced healthcare infrastructure, deep pharmaceutical and biotechnology research pipelines, and high healthcare expenditure. The United States anchors regional growth through its established research ecosystem and rising adoption of nanotechnology-based drug delivery, diagnostics and precision medicine platforms. Canada and Mexico are contributing through expanding healthcare capabilities and research initiatives.

MS Treatment Market to Hit $44.45B by 2034 on DMT Demand

Pune, India – September 24, 2026 -- The global multiple sclerosis treatment market reached USD 26.76 billion in 2025 and is forecast to climb to USD 44.45 billion by 2034, expanding at a 5.8% CAGR, according to a new report from Maximize Market Research.

Disease-modifying therapies and biologics drive current market expansion

Rising MS prevalence, improved diagnostic capabilities, and growing adoption of immunomodulators, immunosuppressants, interferons, oral disease-modifying therapies (DMTs), and monoclonal antibodies are fueling demand across relapsing-remitting (RRMS), primary progressive (PPMS), secondary progressive (SPMS), and clinically isolated syndrome (CIS) patient segments. High-efficacy biologics and oral treatment options are increasingly displacing older therapy classes as patients and physicians prioritize convenience and disease-progression control.

Study: 55% of AD Patients Switch Systemic Therapy Over Efficacy Gaps

Friendswood, Texas – September 24, 2026 -- More than half of atopic dermatitis (AD) patients who used targeted systemic therapies modified treatment because the drugs failed to work, according to a new study published in Dermatology and Therapy by Castle Biosciences, Inc. (Nasdaq: CSTL).

Study finds 55% of systemic therapy users switched due to lack of efficacy

The research surveyed 43 AD patients and caregivers who completed a 32-question assessment at the 2024 National Eczema Association Eczema Expo. Among respondents who had used targeted systemic therapies, 55% reported modifying treatment because of insufficient results. Inadequate skin clearance and persistent itching were cited as the most frequent reasons for switching drugs or adding topical treatments.

Bladder Cancer Treatment Market to Hit $11.33B by 2034

Pune, India – September 24, 2026 -- The global bladder cancer treatment market was valued at $5.13 billion in 2025 and is projected to reach $11.33 billion by 2034, expanding at a 9.2% compound annual growth rate, according to a new analysis from Maximize Market Research.

Immunotherapy and antibody-drug conjugates drive treatment shift

Adoption of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and FGFR inhibitors is accelerating across non-muscle-invasive and muscle-invasive bladder cancer segments. Pharmaceutical companies are directing R&D spend toward intravesical drug delivery, gene therapy, and biomarker-driven precision oncology to improve outcomes for recurrent and metastatic urothelial cancer patients.

BioCytics Taps Eremid Genomics to Sequence Cancer Cell Therapy

Huntersville, N.C. – September 20, 2026 -- BioCytics, Inc. has engaged Eremid Genomic Services to perform single cell transcriptomic and TCR sequencing analysis on immune cells central to its autologous cancer cell therapy program.

Eremid will characterize immune precursor cells before clinical deployment

The North Carolina-based genomics contract research organization will run scRNA-Seq and TCR sequencing on an autologous immune cell fraction supplied by BioCytics. The analysis is designed to confirm whether expanded immune cells are biologically fit for cancer-killing activity and to map their mechanism of action ahead of reinfusion into patients.

NAVER D2SF Backs ImpriMed's $10M Round for AI Cancer Diagnostics

Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.

ImpriMed targets FDA clearance and CLIA certification by Q1 2027 for its blood cancer platform

The company is preparing to commercialize diagnostic products for blood cancers and blood infection in the United States, having already established business partnerships with major U.S. hospitals. ImpriMed's xCellSense platform keeps patient-derived cancer cells viable outside the body for extended periods, allowing evaluation of drug sensitivity alongside genomic, immunophenotypic and clinical data. The company's AI models are trained on more than 3.5 million data points combining real-world data with functional cell analysis.